Literature DB >> 1738022

Oligodendrogliomas: the Mayo Clinic experience.

E G Shaw1, B W Scheithauer, J R O'Fallon, H D Tazelaar, D H Davis.   

Abstract

Eighty-one patients with pure supratentorial oligodendrogliomas underwent surgery alone (19 patients) or surgery plus postoperative radiation therapy (63 patients) between the years 1960 and 1982. The median survival time and the 5-, 10-, and 15-year survival rates for these 82 patients were 7.1 years, 54%, 34%, and 24%, respectively; these values were significantly different from those for an age- and sex-matched normal reference population. Univariate and multivariate survival analyses were performed on 13 possible prognostic factors including: patient age and sex; presence of seizures; site, size, side, computerized tomography (CT) enhancement, grade, and calcification of the tumor; and treatment (extent of surgical resection, lobectomy, radiation dose, and radiation field). Of these factors, tumor grade as classified by the Kernohan and St. Anne-Mayo methods was most strongly associated with survival. Patients with Grade 1 or 2 tumors by either grading method had a median survival time and 5- and 10-year survival rates of approximately 9.8 years. 75%, and 46%, respectively, compared to 3.9 years, 41%, and 20% for those with Grade 3 or 4 tumors. The extent of surgical resection was also associated with survival. The 19 patients who underwent gross total resection of their tumor had a median survival time and 5- and 10-year survival rates of 12.6 years, 74%, and 59%, compared to 4.9 years, 46%, and 23%, respectively, for the 63 who had subtotal resection. When comparing the 19 patients who underwent surgery alone with the 63 who had surgery plus postoperative radiation therapy, there did not appear to be a survival benefit to be gained from the addition of postoperative radiation therapy. However, the patients who had surgery alone tended to have gross total resections and lower tumor grades. Analysis of the subset of 63 patients who underwent subtotal resection alone or with radiation therapy showed that the median survival time and 5- and 10-year survival rates were: 2 years, 25%, and 25% for the eight patients with subtotal resection alone; 4.5 years, 39%, and 20% for the 26 patients with surgery and low-dose (less than 5000 cGy) radiation therapy; and 7.9 years, 62%, and 31% for the 29 patients receiving surgery and high-dose radiation therapy (greater than or equal to 5000 cGy), respectively.

Entities:  

Mesh:

Year:  1992        PMID: 1738022     DOI: 10.3171/jns.1992.76.3.0428

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  52 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging.

Authors:  M Zulfiqar; N Dumrongpisutikul; J Intrapiromkul; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2012-01-19       Impact factor: 3.825

3.  Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Authors:  Yasuo Iwadate; Tomoo Matsutani; Yuzo Hasegawa; Natsuki Shinozaki; Yoshinori Higuchi; Naokatsu Saeki
Journal:  J Neurooncol       Date:  2010-08-19       Impact factor: 4.130

4.  [Extra-cranial anaplastic oligoastrocytoma development from a low-grade glioma].

Authors:  Jorge Molina Saera; Angel Segura Huerta; Laura Palomar Abad; Alejandra Giménez Ortiz; José Ponce Lorenzo; Gaspar Reynés Muntaner
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

5.  Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.

Authors:  Chul-Kee Park; Jin Hyun Kim; Min Jeong Moon; Ji Hye Jung; Su-Young Lim; Sung-Hye Park; Jong-Hoon Kim; Dong Gyu Kim; Hee-Won Jung; Byung-Kyu Cho; Sun Ha Paek
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-26       Impact factor: 4.553

Review 6.  Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.

Authors:  Michael G Brandel; Ali A Alattar; Brian R Hirshman; Xuezhi Dong; Kate T Carroll; Mir Amaan Ali; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2017-04-24       Impact factor: 4.130

7.  Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.

Authors:  Rudolf A Kristof; Georg Neuloh; Volkmar Hans; Martina Deckert; Horst Urbach; Uwe Schlegel; Matthias Simon; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

8.  Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications.

Authors:  F Giammarile; L E Cinotti; A Jouvet; J M Ramackers; G Saint Pierre; P Thiesse; E Jouanneau; J Guyotat; I Pelissou-Guyotat; A Setiey; J Honnorat; D Le Bars; D Frappaz
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

Review 10.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.